Published in J Infect Dis on November 01, 1994
Receptors, mediators, and mechanisms involved in bacterial sepsis and septic shock. Clin Microbiol Rev (2003) 3.70
Comparative proteome analyses of human plasma following in vivo lipopolysaccharide administration using multidimensional separations coupled with tandem mass spectrometry. Proteomics (2005) 1.94
LPS-binding protein protects mice from septic shock caused by LPS or gram-negative bacteria. J Clin Invest (1998) 1.62
The level of lipopolysaccharide-binding protein is significantly increased in plasma in patients with the systemic inflammatory response syndrome. Clin Diagn Lab Immunol (1997) 1.14
Pathogenesis of paralytic ileus: intestinal manipulation opens a transient pathway between the intestinal lumen and the leukocytic infiltrate of the jejunal muscularis. Ann Surg (2002) 0.99
Serum lipopolysaccharide binding protein levels predict severity of lung injury and mortality in patients with severe sepsis. PLoS One (2009) 0.98
Acute-phase concentrations of lipopolysaccharide (LPS)-binding protein inhibit innate immune cell activation by different LPS chemotypes via different mechanisms. Infect Immun (2005) 0.95
Lipopolysaccharide-binding protein for monitoring of postoperative sepsis: complemental to C-reactive protein or redundant? PLoS One (2011) 0.92
Anti-CD14 monoclonal antibodies inhibit the production of tumor necrosis factor alpha and interleukin-10 by human monocytes stimulated with killed and live Haemophilus influenzae or Streptococcus pneumoniae organisms. Infect Immun (1999) 0.90
Inhibitory effect of erythromycin on interleukin 8 production by 1 alpha,25-dihydroxyvitamin D3-stimulated THP-1 cells. Antimicrob Agents Chemother (1996) 0.88
CRISPLD2 is expressed at low levels during septic shock and is associated with procalcitonin. PLoS One (2013) 0.82
Increased levels of lipopolysaccharide binding protein in plasma in children with kawasaki disease. Clin Diagn Lab Immunol (2002) 0.78
Modulation of muramyl dipeptide stimulation of cytokine production by blood components. Clin Exp Immunol (2009) 0.77
Levels of soluble CD14 and lipopolysaccharide-binding protein in human basal tears. Jpn J Ophthalmol (2010) 0.76
CD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein. Science (1990) 17.86
Structure and function of lipopolysaccharide binding protein. Science (1990) 7.76
Receptor-dependent mechanisms of cell stimulation by bacterial endotoxin. Annu Rev Immunol (1995) 6.99
MIF is a pituitary-derived cytokine that potentiates lethal endotoxaemia. Nature (1993) 5.60
ESCMID* guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients. Clin Microbiol Infect (2012) 4.56
Lipopolysaccharide activation of human endothelial and epithelial cells is mediated by lipopolysaccharide-binding protein and soluble CD14. Proc Natl Acad Sci U S A (1993) 4.35
Treatment of gram-negative bacteremia and shock with human antiserum to a mutant Escherichia coli. N Engl J Med (1982) 4.28
Leptospiral lipopolysaccharide activates cells through a TLR2-dependent mechanism. Nat Immunol (2001) 4.13
Protection from septic shock by neutralization of macrophage migration inhibitory factor. Nat Med (2000) 3.89
Isolation of a lipopolysaccharide-binding acute phase reactant from rabbit serum. J Exp Med (1986) 3.84
Intracellular action of the cytokine MIF to modulate AP-1 activity and the cell cycle through Jab1. Nature (2000) 3.81
CD14 is a pattern recognition receptor. Immunity (1994) 3.79
An essential regulatory role for macrophage migration inhibitory factor in T-cell activation. Proc Natl Acad Sci U S A (1996) 3.79
Purification, bioactivity, and secondary structure analysis of mouse and human macrophage migration inhibitory factor (MIF). Biochemistry (1994) 3.58
Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. The Swiss HIV Cohort Study. Circulation (1999) 3.16
MIF regulates innate immune responses through modulation of Toll-like receptor 4. Nature (2002) 3.10
Lipopolysaccharide is in close proximity to each of the proteins in its membrane receptor complex. transfer from CD14 to TLR4 and MD-2. J Biol Chem (2001) 2.94
Gram-positive cell walls stimulate synthesis of tumor necrosis factor alpha and interleukin-6 by human monocytes. Infect Immun (1994) 2.92
Recognition of gram-negative bacteria and endotoxin by the innate immune system. Curr Opin Immunol (1999) 2.85
Natural history of aortic valve endocarditis in rats. Infect Immun (1982) 2.74
Lipopolysaccharide (LPS) binding protein opsonizes LPS-bearing particles for recognition by a novel receptor on macrophages. J Exp Med (1989) 2.72
Bacteremia due to viridans streptococcus in neutropenic patients with cancer: clinical spectrum and risk factors. Clin Infect Dis (1994) 2.61
Prognostic values of tumor necrosis factor/cachectin, interleukin-1, interferon-alpha, and interferon-gamma in the serum of patients with septic shock. Swiss-Dutch J5 Immunoglobulin Study Group. J Infect Dis (1990) 2.36
Successful single-dose amoxicillin prophylaxis against experimental streptococcal endocarditis: evidence for two mechanisms of protection. J Infect Dis (1983) 2.35
Fluconazole prophylaxis prevents intra-abdominal candidiasis in high-risk surgical patients. Crit Care Med (1999) 2.35
Correlation between in vitro susceptibility of Candida albicans and fluconazole-resistant oropharyngeal candidiasis in HIV-infected patients. Eur J Clin Microbiol Infect Dis (1993) 2.35
Potent synergism of the combination of fluconazole and cyclosporine in Candida albicans. Antimicrob Agents Chemother (2000) 2.27
Toll-like receptor 4, but not toll-like receptor 2, is a signaling receptor for Escherichia and Salmonella lipopolysaccharides. J Immunol (2000) 2.16
Adaptation to bacterial lipopolysaccharide controls lipopolysaccharide-induced tumor necrosis factor production in rabbit macrophages. J Clin Invest (1990) 2.12
Transfection of CD14 into 70Z/3 cells dramatically enhances the sensitivity to complexes of lipopolysaccharide (LPS) and LPS binding protein. J Exp Med (1992) 2.05
Migration inhibitory factor expression in experimentally induced endotoxemia. Am J Pathol (1997) 2.00
An essential role for macrophage migration inhibitory factor in the tuberculin delayed-type hypersensitivity reaction. J Exp Med (1996) 1.99
Binding of bacterial peptidoglycan to CD14. J Biol Chem (1998) 1.97
New strategies for clinical trials in patients with sepsis and septic shock. Crit Care Med (2001) 1.95
Interferon gamma receptor deficient mice are resistant to endotoxic shock. J Exp Med (1994) 1.95
Endotoxin induces rapid protein tyrosine phosphorylation in 70Z/3 cells expressing CD14. J Biol Chem (1993) 1.93
MD-2 binds to bacterial lipopolysaccharide. J Biol Chem (2001) 1.91
BAL9141, a novel extended-spectrum cephalosporin active against methicillin-resistant Staphylococcus aureus in treatment of experimental endocarditis. Antimicrob Agents Chemother (2002) 1.88
Control of lipopolysaccharide (LPS) binding and LPS-induced tumor necrosis factor secretion in human peripheral blood monocytes. J Immunol (1992) 1.82
Escherichia coli resistant to fluoroquinolones in patients with cancer and neutropenia. N Engl J Med (1994) 1.81
Recognition of endotoxin by cells leading to transmembrane signaling. Curr Opin Immunol (1994) 1.67
Plasma lipopolysaccharide (LPS)-binding protein. A key component in macrophage recognition of gram-negative LPS. J Immunol (1992) 1.66
Comparative efficacy of amoxicillin-clavulanate, cloxacillin, and vancomycin against methicillin-sensitive and methicillin-resistant Staphylococcus aureus endocarditis in rats. J Infect Dis (1989) 1.64
Treatment of experimental endocarditis due to erythromycin-susceptible or -resistant methicillin-resistant Staphylococcus aureus with RP 59500. Antimicrob Agents Chemother (1995) 1.63
Suppression of proinflammatory cytokines in monocytes by a tetravalent guanylhydrazone. J Exp Med (1996) 1.61
Fluconazole plus cyclosporine: a fungicidal combination effective against experimental endocarditis due to Candida albicans. Antimicrob Agents Chemother (2000) 1.61
Levofloxacin versus ciprofloxacin, flucloxacillin, or vancomycin for treatment of experimental endocarditis due to methicillin-susceptible or -resistant Staphylococcus aureus. Antimicrob Agents Chemother (1997) 1.58
Glycosyl-phosphatidylinositol-anchored or integral membrane forms of CD14 mediate identical cellular responses to endotoxin. Proc Natl Acad Sci U S A (1993) 1.55
Oropharyngeal candidiasis resistant to single-dose therapy with fluconazole in HIV-infected patients. AIDS (1994) 1.55
ESCMID* guideline for the diagnosis and management of Candida diseases 2012: adults with haematological malignancies and after haematopoietic stem cell transplantation (HCT). Clin Microbiol Infect (2012) 1.55
Localization of macrophage migration inhibitory factor (MIF) to secretory granules within the corticotrophic and thyrotrophic cells of the pituitary gland. Mol Med (1995) 1.55
Lipopolysaccharide (LPS) signal transduction and clearance. Dual roles for LPS binding protein and membrane CD14. J Biol Chem (1995) 1.54
Bacteremia due to viridans streptococci in neutropenic patients: a review. Am J Med (1994) 1.53
Cathelicidin family of antibacterial peptides CAP18 and CAP11 inhibit the expression of TNF-alpha by blocking the binding of LPS to CD14(+) cells. J Immunol (2001) 1.52
Cytokines, nitrite/nitrate, soluble tumor necrosis factor receptors, and procalcitonin concentrations: comparisons in patients with septic shock, cardiogenic shock, and bacterial pneumonia. Crit Care Med (1997) 1.50
Limited CD4+ T-cell renewal in early HIV-1 infection: effect of highly active antiretroviral therapy. Nat Med (1998) 1.50
Beta-lactam resistance mechanisms of methicillin-resistant Staphylococcus aureus. J Infect Dis (1991) 1.50
Comparative efficacy of daptomycin, vancomycin, and cloxacillin for the treatment of Staphylococcus aureus endocarditis in rats and role of test conditions in this determination. Antimicrob Agents Chemother (1990) 1.49
Lipopolysaccharide binding protein enhances the responsiveness of alveolar macrophages to bacterial lipopolysaccharide. Implications for cytokine production in normal and injured lungs. J Clin Invest (1992) 1.48
Prevention of gram-negative shock and death in surgical patients by antibody to endotoxin core glycolipid. Lancet (1985) 1.47
Efficacies of moxifloxacin, ciprofloxacin, and vancomycin against experimental endocarditis due to methicillin-resistant Staphylococcus aureus expressing various degrees of ciprofloxacin resistance. Antimicrob Agents Chemother (2001) 1.47
Increased circulating soluble CD14 is associated with high mortality in gram-negative septic shock. J Infect Dis (1995) 1.43
An epidemic of food-borne listeriosis in western Switzerland: description of 57 cases involving adults. Clin Infect Dis (1995) 1.43
Control of lipopolysaccharide-high density lipoprotein binding by acute phase protein(s). J Immunol (1983) 1.42
ESCMID* guideline for the diagnosis and management of Candida diseases 2012: diagnostic procedures. Clin Microbiol Infect (2012) 1.41
The mouse brain transcriptome by SAGE: differences in gene expression between P30 brains of the partial trisomy 16 mouse model of Down syndrome (Ts65Dn) and normals. Genome Res (2000) 1.40
Biochemical and mutational investigations of the enzymatic activity of macrophage migration inhibitory factor. Biochemistry (1997) 1.40
Role of amoxicillin serum levels for successful prophylaxis of experimental endocarditis due to tolerant streptococci. J Infect Dis (1994) 1.40
Multiplex blood PCR in combination with blood cultures for improvement of microbiological documentation of infection in febrile neutropenia. J Clin Microbiol (2010) 1.38
Macrophage migration inhibitory factor release by macrophages after ingestion of Plasmodium chabaudi-infected erythrocytes: possible role in the pathogenesis of malarial anemia. Infect Immun (2000) 1.37
Campylobacter fetus subspecies fetus bacteremia. Arch Intern Med (1985) 1.35
Birefringence of muscle proteins and the problem of structural birefringence. Biochim Biophys Acta (1968) 1.35
Identification of lipopolysaccharide-binding proteins in 70Z/3 cells by photoaffinity cross-linking. J Biol Chem (1990) 1.33
CD14 receptor-mediated uptake of nonopsonized Mycobacterium tuberculosis by human microglia. Infect Immun (1995) 1.33
Cytokine production after intravenous or peritoneal gram-negative bacterial challenge in mice. Comparative protective efficacy of antibodies to tumor necrosis factor-alpha and to lipopolysaccharide. J Immunol (1992) 1.33
Treatment of gram-negative septic shock with human IgG antibody to Escherichia coli J5: a prospective, double-blind, randomized trial. J Infect Dis (1988) 1.32
Lipopolysaccharide-binding protein as a major plasma protein responsible for endotoxemic shock. Proc Natl Acad Sci U S A (1993) 1.31
Septic shock: treatment. Lancet (1991) 1.31
Piperacillin-tazobactam plus amikacin versus ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer. Antimicrob Agents Chemother (1995) 1.31
IFN-gamma involvement in the severity of gram-negative infections in mice. J Immunol (1993) 1.30